1. Home
  2. MLYS vs RYI Comparison

MLYS vs RYI Comparison

Compare MLYS & RYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • RYI
  • Stock Information
  • Founded
  • MLYS 2019
  • RYI 1842
  • Country
  • MLYS United States
  • RYI United States
  • Employees
  • MLYS N/A
  • RYI 4300
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • RYI Metal Fabrications
  • Sector
  • MLYS Health Care
  • RYI Industrials
  • Exchange
  • MLYS Nasdaq
  • RYI Nasdaq
  • Market Cap
  • MLYS 634.6M
  • RYI 654.8M
  • IPO Year
  • MLYS 2023
  • RYI N/A
  • Fundamental
  • Price
  • MLYS $9.83
  • RYI $20.58
  • Analyst Decision
  • MLYS Strong Buy
  • RYI Hold
  • Analyst Count
  • MLYS 2
  • RYI 1
  • Target Price
  • MLYS $30.00
  • RYI $28.00
  • AVG Volume (30 Days)
  • MLYS 238.6K
  • RYI 275.3K
  • Earning Date
  • MLYS 11-11-2024
  • RYI 02-19-2025
  • Dividend Yield
  • MLYS N/A
  • RYI 3.66%
  • EPS Growth
  • MLYS N/A
  • RYI N/A
  • EPS
  • MLYS N/A
  • RYI 0.64
  • Revenue
  • MLYS N/A
  • RYI $4,703,700,000.00
  • Revenue This Year
  • MLYS N/A
  • RYI N/A
  • Revenue Next Year
  • MLYS N/A
  • RYI $1.76
  • P/E Ratio
  • MLYS N/A
  • RYI $32.25
  • Revenue Growth
  • MLYS N/A
  • RYI N/A
  • 52 Week Low
  • MLYS $7.95
  • RYI $17.18
  • 52 Week High
  • MLYS $16.91
  • RYI $36.15
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 35.13
  • RYI 53.31
  • Support Level
  • MLYS $8.60
  • RYI $17.18
  • Resistance Level
  • MLYS $13.37
  • RYI $18.73
  • Average True Range (ATR)
  • MLYS 0.92
  • RYI 0.75
  • MACD
  • MLYS -0.34
  • RYI 0.36
  • Stochastic Oscillator
  • MLYS 25.47
  • RYI 99.85

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About RYI Ryerson Holding Corporation

Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. Its customers range from local, independently owned fabricators and machine shops to large, international original equipment manufacturers. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company generates substantially all of its revenue from sales of metal products. Geographically, the majority is from the United States.

Share on Social Networks: